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An analysis of large structural 
variation in global Plasmodium 
falciparum isolates identifies a 
novel duplication of the chloroquine 
resistance associated gene
Matt Ravenhall  1, ernest Diez Benavente  1, Colin J. sutherland  2, David A. Baker  1, 
susana Campino1 & taane G. Clark  1,3
the evolution of genetic mechanisms for host immune evasion and anti-malarial resistance has 
enabled the Plasmodium falciparum malaria parasite to inflict high morbidity and mortality on 
human populations. Most studies of P. falciparum genetic diversity have focused on single-nucleotide 
polymorphisms (SNPs), assisting the identification of drug resistance-associated loci such as the 
chloroquine related crt and sulfadoxine-pyrimethamine related dhfr. Whilst larger structural variants 
are known to impact adaptation, for example, mdr1 duplications with anti-malarial resistance, no large-
scale, genome-wide study on clinical isolates has been undertaken using whole genome sequencing 
data. By applying a structural variant detection pipeline across whole genome sequence data from 
2,855 clinical isolates in 21 malaria-endemic countries, we identified >70,000 specific deletions and 
>600 duplications. Most structural variants are rare (48.5% of deletions and 94.7% of duplications are 
found in single isolates) with 2.4% of deletions and 0.2% of duplications found in >5% of global isolates. 
A subset of variants was present at high frequency in drug-resistance related genes including mdr1, the 
gch1 promoter region, and a putative novel duplication of crt. Regional-specific variants were identified, 
and a companion visualisation tool has been developed to assist web-based investigation of these 
polymorphisms by the wider scientific community.
Plasmodium falciparum malaria imposes a heavy morbidity and mortality burden, with an estimated 216 million 
new cases and 446,000 deaths in 2016 alone, with ~90% of the burden in sub-Saharan Africa1. An understand-
ing of the genomic diversity of P. falciparum parasites could provide insights into novel phenotypes that impact 
responses to antimalarials and other control measures, as well as host-pathogen interactions. Single nucleotide 
polymorphism (SNP) based analyses have revealed insights into drug resistance, molecular barcodes for conti-
nental origin2, transmission dynamics3, multiplicity of infection4 and regions under selective pressure related to 
immunological and anti-malarial treatment pressure5. In comparison, investigations of structural variants (SVs), 
such as insertions, deletions and duplications, have been sparse. This is despite SVs making an important con-
tribution to genomic diversity and comprising many nucleotides of heterogeneity. In particular, copy number 
variants (CNVs; large indels and duplications) are thought to be widespread in the P. falciparum genome6.
Malaria parasites are exposed to strong selection from the human immune response and treatment with anti-
malarial drugs. Subsequently, CNVs have often been found in association with specific P. falciparum phenotypes, 
such as drug resistance. Duplications of mdr1 have been shown to underlie a multi-drug resistance phenotype, 
with these variants now present at high population frequencies in Southeast Asia7, with copy number altering the 
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parasite response to multiple anti-malarial drugs8. Recently, we identified a novel promoter duplication for gch1 
at near-fixation in a Malawi population5, which is distinct from the whole gene duplication observed in Southeast 
Asia known to contribute to sulfadoxine-pyrimethamine (SP) resistance. In general, such regional genetic varia-
tion may arise from differences in drug regimens, mosquito vectors, and host immunity, but is poorly understood.
Given their importance, a genome-wide structural variant map for P. falciparum with country and regional res-
olution should provide insights with which to better understand the impacts of treatment regimes, assess changes in 
parasite diversity, and ultimately inform the roll-out of anti-malarial drugs and other control initiatives. The advent 
of microarray technologies, such as genomic hybridisation arrays (CGH), has improved methods for detecting and 
confirming known SVs9,10. However, studies of this type have typically featured modest sample sizes and focused on 
the exome of lab-adapted isolates. The largest array-based study in P. falciparum clinical isolates (n = 122) identified 
134 high-confidence CNVs across the parasite exome, established they were more common in South American than 
African or Southeast Asian populations, and identified several loci including mdr1, rh2b, and histidine-rich proteins II 
and III to be under positive selection10. Recently whole genome sequencing platforms, which produce a greater depth 
of short or long reads, have been used to detect SVs in P. falciparum strains11,12, and have potentially finer resolution 
than array-based approaches. Coupled with bioinformatic advances in detection algorithms, there is now capacity 
to accurately characterise a broader range of SV types. For example, extremes in coverage can identify duplications 
and deletions, split sequences and alternative de novo assembly-based approaches can detect a number of other types, 
including inversions and large insertions and deletions13.
By analysing whole genome sequencing data from 2,855 clinical isolates and focusing on robust genomic 
regions (82.6%) of the AT-rich P. falciparum genome, we present the first comprehensive genomic map of SVs 
within the global P. falciparum population, with a focus on CNVs. We identify a total of 70,257 high quality 
deletions (mean 440.56 per isolate, median size 26 bp) and 601 high quality duplications (mean 0.43 per isolate, 
median size 1,478 bp), contrasting with an average of 24,495 SNPs and 33,479 small indels (<15 bp) per isolate. 
Several variants were found to be geographically specific and highlight novel structural variants with roles in 
antigenic variation, drug resistance, and host-pathogen interactions. We confirm specific variants using several 
alternative approaches, including the analysis of PacBio long-read data of P. falciparum laboratory strains.
Results
Distribution of variant type, size and location. The 2,855 isolates represented 21 countries across 
Africa (Central, East, West), Asia (South, Southeast) and South America (Supplementary Table 1), and all dis-
played minimal evidence of multiplicity of infection (based on genome-wide SNPs) and non-anomalous coverage 
(see Methods). Using a structural variant (SV) discovery pipeline based primarily upon DELLY13, we identified 
more than 1 million putative variants deletions and duplications relative to the 3D7 reference genome, across 
robust regions (~83%; excluding regions that were highly variable or within 100 kbp of a chromosome end) of the 
P. falciparum genome. SVs of length greater than 300 bp were present in 4,941 genes, including in known drug 
resistance candidates (e.g. crt, mdr1, gch1) and indel/duplication hotspots, such as within the liver stage antigen 
LSA114, the gametocyte specific Pf11-114 and invasion-related Rh2b15 and EBA175 (PF3D7_0731500)16 genes (see 
Supplementary Table 2 for the 117 genes with >1% SV frequency). This raw set was filtered using a popula-
tion-based SV analysis pipeline (see Methods), and the resulting dataset of 70,858 ‘high-quality’ variants included 
70,257 deletions (mean 440.56 per isolate, median size 26 bp; 91.8% very small or micro <300 bp) and 601 dupli-
cations (mean 0.43 per isolate, median 1,478 bp; 16.1% very small or micro <300 bp). Most duplications (94.7%) 
and half of deletions (34,065 deletions; 48.6%) were unique to single isolates (total: 34,634; 34,065 deletions and 
569 duplications) (Fig. 1). Both deletions and duplications tend to occur within intergenic regions (intergenic/
genic ratio: deletions 1.42, duplications 2.15), and there is disproportional increase in the density of duplications 
in chromosomes 5 and 12, due to known drug resistance loci (mdr1, gch1) (Fig. 1). The most frequent genes with 
high-quality SVs (>300 bp) reveals loci that include both deletions and duplications (e.g. LSA3), and clusters of 
duplications (e.g. in chromosome 11: FP3, ApiAP2, CYP19B, FP2A, TREP) (Supplementary Table 3). Therefore, 
a (1 kbp) window-based analysis was used to identify regions with overlapping but distinct SVs, thereby assisting 
with refining their breakpoints. For deletions, 24,947 (of 27,388) windows (78.1% genic) were represented, com-
pared to 2,441 windows (80.4% genic) for duplications.
Frequently occurring specific variants. Previous work has shown that SVs present in a relatively high 
proportion of the global population are consistent with evidence of phenotypic selection10, we therefore priori-
tised common variants, that is, present in at least 1% of our isolates (29 or more). In total we identify 7,618 com-
mon variants of which only two are duplications, one being the previously identified 436 bp gch1 promoter region 
duplication5 and the other being a 252 bp intergenic duplication (11:1029648–1029899; between PF3D7_1126300 
and PF3D7_1126400) and exclusive to Southeast Asia. Of all common variants, 2,780 (36.5%) are genic and 
the median length is 25 bp (see Supplementary Table 4 for the subset with global frequency >35%). At a mini-
mum frequency of 5%, there were 1,676 variants with median length 27 bp, including 723 (43.1%) genic and 1 
duplication (gch1). We focused primarily on SVs in excess of 300 bp in length, as DELLY calling is considered 
more reliable at this threshold13. Only 36 loci or regions with common variants greater than 300 bp in length 
(Supplementary Table 5) were identified, including four intergenic deletions (size range: 605 to 1,023 bp), and 
one 553 bp deletion in LSA3 (PF3D7_0220000). Interestingly the 553 bp deletion in LSA3 is present primarily in 
Southeast Asia, particularly Thailand (14.6%), Laos (11.5%), and Myanmar (11.2%) (Global 5.5%; Africa 0.1%, 
America 0.0%, Asia 10.2%), and may represent region-specific host-directed selection. Two of the intergenic var-
iants show evidence of continental differences (Allele frequency difference: FST score >0.2), including a 1,015 bp 
deletion in chromosome 9 upstream of gexp22 (PF3D7_0935500) (FST: 0.227; Africa 13.2%, America 70.8%, Asia 
41.7%) and a 605 bp deletion in chromosome 12 upstream of ap2mu (PF3D7_1218300) (FST 0.249; 0.2% Africa, 
0.0% America, 33.6% Asia).
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exploration of structural variation in anti-malarial resistance candidates. Previous analyses have 
revealed evidence of structural variation in loci associated drug resistance (e.g. gch1). Given that SVs can have a 
significant impact on gene expression and anti-malarial resistance, we focused an analysis on the identification 
of novel structural variants in candidate genes (dhfr, dhps, kelch13, mdr1, gch1, crt). Despite removing mixed 
infections determined using genome-wide SNPs, it is possible for heterogeneous duplications (i.e. differences 
in genetic copies) to display as mixed genotype calls, therefore we extended our ‘high-quality’ dataset to include 
those duplications previously excluded for high rates of the heterozygous genotype. The resulting ‘high-quality 
relaxed’ dataset included 91,936 putative variants (70,257 deletions: mean 440.56 per isolate, median size 26 bp; 
21,679 duplications: mean 10.92 per isolate, median 1,354 bp). To minimise the number of false positives, we 
manually verified the alignments for all candidate regions specifically mentioned here. Overall, no high-quality 
SVs were identified in SP resistance associated dhfr (PF3D7_0417200) or dhps (PF3D7_0810800) genes, or arte-
misinin resistance associated kelch13 (PF3D7_1343700). We identify 115 specific duplication types containing 
mdr1 in 189 isolates, primarily in Southeast Asia (Southeast Asia 12.9%; Cambodia 9.5%, Myanmar 11.9%, 
Papua New Guinea 3.8%, Thailand 29.0%, Vietnam 5.9%), and near absent in Africa (Africa 0.10%; Ghana 0.2%) 
(Fig. 2), consistent with previous reports17. Similarly, tandem duplications are also present in KE01 (Kenya) and 
KH01 (Cambodia) within our complementary PacBio-based dataset (n = 13).
The whole gene duplication of gch1 (PF3D7_1224000) and a recently identified 436 bp gch1 promoter dupli-
cation may be linked to SP resistance5. We identify 307 isolates with 135 distinct forms of whole gene duplication 
across gch1 (9.9% of the total dataset) (Fig. 3). Similar whole gene tandem duplications were present in PacBio 
isolates for 7G8 and KH02, as a triplication in GB4, and as a triplication with an inverted middle copy in DD2; 
this being consistent with the existing literature12. In contrast, 491 high quality isolates are positive for the previ-
ously identified 436 bp specific ‘promoter region’ duplication (14.0% of total). We confirm this duplication being 
present at near-fixation in Malawi (89.5%), frequent in the rest of East Africa (Tanzania 78.5%, Kenya 31.6%), 
maintained in West Africa (Gambia 6.1%, Ghana 4.3%, Guinea 22.2%) and Central Africa (Democratic Republic 
of Congo 26.3%), but absent from all Asian and American isolates (Regional FST 0.554). No such duplication was 
found in any of the validation isolates with PacBio sequencing data (n = 13), though none of these were isolated 
from Malawi. These data therefore support the gch1 promoter duplication being present at notable frequency 
across Africa, and the need for further functional characterisation of any potential role in SP resistance.
Finally, we uncover evidence of duplications of crt (PF3D7_0709000) across 35 West African and 2 Cambodian 
isolates. A 22.9 kbp duplication of crt is present and consistent across 32 isolates sourced in West Africa (4.3%), 
specifically sub-populations isolated in Burkina Faso (n = 14, 29.2%), Ghana (n = 15, 3.4%), Guinea (n = 1, 
Figure 1. High quality variants by position, length and per-chromosome. (A) Distribution of deletions by 
size categories. (B) Distribution of duplications by size categories. (C) Distribution of distinct form of deletion 
across each chromosome. (D) Distribution of distinct forms of duplication across each chromosome.
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0.85%) and Mali (n = 1, 1.8%). Those 32 isolates display 26 specific variants, the consensus of which suggests 
that the duplication is most likely approximately 22,893 bp in length, and therefore includes several genes 
(PF3D7_0708900 (sco1), PF3D7_0709000 (crt), PF3D7_0709050 (small nucleolar RNA), PF3D7_0709100 (cg1), 
PF3D7_0709200 (glp3) and PF3D7_0709300 (cg2)) (Fig. 4). A further three isolates (2 from Ghana, 1 from 
Burkina Faso) display a similar 28.7 kbp duplication, which also includes PF3D7_0708800 (heat shock protein 
110) and may be under different selective pressure. Beyond Africa, two Cambodian isolates feature smaller 702 bp 
and 11,844 bp duplications. No crt duplication was present in the validation (PacBio) dataset (n = 13). To explore 
the specific variability of crt in West Africa, we calculated the abundance of resistance-associated haplotypes 
(alleles) directly from raw reads, finding that only both CVMNK (chloroquine susceptible) and CVIET (chloro-
quine resistant) haplotypes were present in all 35 duplication-positive isolates; this compared to 20.3% (133/656) 
of isolates with evidence for mixed haplotypes but no evidence of duplication (Supplementary Table 6). Increasing 
the stringency on the calling of genotypes led to the retention of a disproportional number of mixed haplotypes 
in those samples with duplications (at least 2 (10) reads required to call haplotypes: duplications 33/35 (24/35) vs. 
no duplications 99/133 (44/133)). For those isolates with mixed haplotype calls (n = 168), the levels of crt gene 
to chromosome 7-wide coverage were greater in the duplication group (ratio median: duplication group (n = 35) 
1.10 vs non-duplication (n = 133) 0.74; Wilcoxon P = 1.7 × 10−10). There was no difference in the coverage ratio 
within the non-duplication group (ratio median: mixed haplotypes (n = 133) 0.74 vs. single haplotype (n = 523) 
0.76; Wilcoxon P = 0.09). These observations lend support to the robustness of duplications in crt. The proportion 
of CVIET haplotype reads in the duplication-positive group (median 0.53; IQR: 0.31–0.57; Supplementary Fig. 1) 
suggested a degree of parity of the carriage of chloroquine susceptible and resistant forms, and contrasted with 
Figure 2. Coverage plots showing examples of isolates with three types of mdr1 duplications. (A) No 
duplication in a Democratic Republic of Congo isolate. (B) Duplication in a Cambodian isolate. (C) Duplication 
in a Thai isolate; Blue traces represents the per base coverage for each isolate. Orange region indicates the 
predicted structural variant; Green region indicates the gene of interest, Grey indicates neighbouring genes; 
horizontal line is the median coverage for the isolate.
Figure 3. Coverage plots showing examples of isolates with three types of gch1 duplications. (A) No duplication 
in a Cambodian isolate. (B) Promoter duplication in a Malawian isolate. (C) Gene Duplication in a Cameroon 
isolate; Blue traces represent the per base coverage for each isolate. Orange region indicates the predicted 
structural variant; Green region indicates the gene of interest, Grey indicates neighbouring genes; horizontal 
line is the median coverage for the isolate.
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other West African isolates without duplications (Wilcoxon P = 0.02; Supplementary Fig. 1). It is unclear, without 
additional transcriptional analysis, whether these forms are expressed independently though we hypothesise that 
the presence of both forms may allow individual parasites to benefit from the resistance form whilst reducing 
associated fitness costs. If so, a heterogeneous duplication of this sort may represent a more evolutionarily resil-
ient form of crt-associated resistance.
Population-Specific Variants. Regional differences (across West Africa, Central Africa, East Africa, South 
Asia, Southeast Asia, South America) in SV frequencies were quantified with FST analysis for all high-quality vari-
ants (median (range): deletions 0.002 (0–0.613); duplications 0.001 (0–0.554)). A total of 153 high quality variants 
(152 deletions and one duplication) have strong regional differences (FST > 0.2), including: (i) an Asia-specific 
59 bp deletion within the hypothetical protein PF3D7_0312900 (FST 0.613, 69.8% South Asia, 70.9% Southeast 
Asia, 0.0% Rest of the World), (ii) a 40 bp South America-specific deletion in the putative histone deacetylase 
PF3D7_1472200 (FST 0.497, 54.2% South America, 0.0% Rest of the World), and (iii) the 436 bp gch1 promoter 
region duplication (FST 0.554, 78.0% East Africa, 17.2% Central Africa, 6.8% West Africa, 0.0% Rest of the World) 
(Supplementary Table 7).
Extending our analysis to the full list of SVs detected by the DELLY pipeline that were confirmed using alter-
native coverage-based approaches (CNVNator or Control-FREEC software), we identity several SVs with bioge-
ographical specificity. Non-drug resistance candidates include a 169 bp deletion within the rhoptry-associated 
membrane antigen PF3D7_0707300 (FST 0.354; 46.0% Africa, 0.6% Asia, 0.0% America) and a 370 bp deletion in 
the ring-infected erythrocyte surface antigen PF3D7_0102200 (FST 0.213; Africa 40.3%, Asia 4.2%, America 4.2%) 
with elevation in West and Central Africa (FST 0.321; West Africa 66.1%, Central Africa 36.1%, East Africa 4.1%, 
South Asia 50.9%, Southeast Asia 2.5%, South America 4.2%). We also identify a near Africa-specific 586 bp dele-
tion within the C-terminal of reticulocyte binding protein 2 homologue b (rh2b, PF3D7_1335300) (FST: 0.334; 
58.4% Africa, 12.5% America, 1.3% Asia) and a 29 bp deletion in rhopH2 (PF3D7_0929400) (FST 0.288; 73.7% 
Africa, 100% America, 40.8% Asia), knockdown of which has been shown to inhibit parasite growth within host 
erythrocytes18. These findings were supported by manual inspection of coverage depth and split read support.
Discussion
This large and geographically comprehensive study of SVs in P. falciparum characterises both known and novel 
variants, the latter occurring in loci associated with antimalarial resistance, host-pathogen interactions, and dis-
ease severity. Deletions represent the bulk of SVs (>99%) identified, primarily due to an abundance of shorter 
forms (median 26 bp) in comparison to duplications (median 713 bp). We find that 48.6% of high quality dele-
tions and 65.0% of high quality duplications were found in single isolates, in line with previous work with smaller 
sample sizes including a recent study which found that approximately half of structural variants were only present 
in one of 16 isolates9. Previous large-scale studies have often overlooked the role of smaller structural variants (15 
to 500 bp), defining and applying a minimum size of 500 bp. Our results demonstrate that a significant number 
(97.7%) of high quality variants are present in the 15 to 500 bp size range, indicating that previous studies may 
have under-estimated the full range of genomic variants within the P. falciparum genome. This finding that most 
SVs are under 500 bp in size is consistent with previous studies in various species9,19.
Population-specific SVs suggest evidence of localised selective pressure10. These include the drug resistance 
associated mdr1 and gch1 genes, and a striking novel 22.9 kbp duplication of the chloroquine resistance associated 
gene crt, for which isolates are positive for both the CVMNK (chloroquine susceptible) and CVIET (chloroquine 
resistant) forms of the gene across multiple independent West African sub-populations. Whilst, the putative crt 
Figure 4. Coverage plots showing examples of isolates with three types of crt duplications. (A) No duplication 
in a Bangladesh isolate. (B) Gene duplication in a Ghanaian isolate. (C) Gene duplication in a Burkina Faso 
isolate; Blue traces represents the per base coverage for each isolate. Orange region indicates the predicted 
structural variant; Green region indicates the gene of interest, Grey indicates neighbouring genes; horizontal 
line is the median coverage for the isolate.
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duplications need to be confirmed, the detection of those variants in isolates with a balanced number of CVMNK 
and CVIET haplotypes was robust to increasing the stringency on the number of supporting sequencing reads. It 
is unclear whether dual-carriage of these variants would allow expression of both or either forms of the crt trans-
porter, though it is likely that this could allow individual parasites to benefit from chloroquine resistance with 
a reduced fitness cost. This finding is similar to previously identified alternatively spliced forms of crt in eastern 
Sudan which were hypothesised to facilitate ‘switching’ between chloroquine resistant and susceptible isoforms20. 
Further short ~29 bp and ~430 bp deletions identified here at low frequency in crt may reflect the specific dele-
tions identified in that same study. Follow up studies, particularly with culture-adapted clinical isolates in which 
this duplication is present, are required to properly characterise in vitro phenotypes. We also present further char-
acterisation of the promoter region duplication for the SP resistance associated gene gch1, previously identified in 
Malawi5. This additional analysis confirms the duplication is at near-fixation in Malawi, and highlights its pres-
ence across Central and East Africa, including notably high frequencies in Tanzania, Kenya, Guinea and the DRC. 
Further this genetic region has been shown to be under positive selection in Malawi using SNP-based metrics5.
Our results demonstrate that application of our pipeline can enhance the speed and capacity of high through-
put structural variant discovery. However, this is not without limitations, especially as we rely upon validity of the 
underlying mapping, for which some regions (such as those which are highly variable or repetitive) are known 
to be difficult to characterise. To resolve this issue, we excluded known highly variable regions from our analysis, 
such as var, rifin and stevor genes and subtelomeric regions. However, in doing so we prevent discovery of true 
variants within these regions, including duplications in AT-rich loci12. In addition, all variants found were identi-
fied relative to the 3D7 reference strain, consistent with the approach taken in other studies9,10. Given that 3D7 is 
most likely an African strain, SVs within African isolates may be artificially under-represented due to those var-
iants also being present within 3D7. Further, the discovery stage of our pipeline inherits the limitations of those 
tools, such as an inability to infer high quality inversions. This risk was limited by prioritising those variants that 
were identified by DELLY with support from an alternative discovery software (CNVNator or Control-FREEC).
The approach taken in this study, as with standard SNP discovery, requires single-genotype samples, preventing 
investigation of more complex isolates. By pre-screening for non-complex infections and also filtering on rates of pre-
dicted genotype, we were able to reduce false positive calls but also removed several highly likely variants that presented 
with a high prevalence of predicted heterozygous calls and potentially underestimate the total number of duplications. 
Notable candidate variants excluded from our high-quality dataset but supported by manual inspection of coverage 
depth or similar variants within the existing scientific literature include 102 putative deletions within the glycophorin 
A binding, invasion-critical gene EBA175 (PF3D7_0731500)16, the most prominent being a 424 bp deletion in 1,492 
isolates (30.5% of isolates). We also identify a 586 bp deletion elevated in Africa (58.4% Africa, 12.5% America, 1.3% 
Asia) within Rh2b, a gene that plays a key role in erythrocyte invasion15. Similar deletions have previously been iden-
tified (and validated here) in the T996 P. falciparum line21 and in isolates from Senegal, where it is possibly associated 
with the utilisation of neuraminidase-sensitive invasion pathways22. Another variant is a 29 bp deletion in rhopH2 
(PF3D7_0929400), which has a reduced prevalence in Asian populations, and knockdowns of which have been shown 
to inhibit parasite growth within host erythrocytes16.
Our final count of 70,858 high quality specific variants assumes that each SV is distinct by their specific base-pair 
location. This means that we identify variants which arose from similar evolutionary events but may place insufficient 
emphasis on variants with a shared phenotypic impact. Previous studies collapsed analysis to a locus level, but risk over-
looking complex structural variation within the same gene. This challenge was partially resolved via our windows-based 
approach, whereby variants are grouped due to their presence within a 1 kbp window.
Overall, our work presents a set of high-quality SVs, some population specific, which are likely to have func-
tional consequences for drug resistance and erythrocyte invasion. An extended list of further structural variation 
requires both technological advances, such as low cost long read platforms with low error rates, as well as com-
putational and algorithmic advances that assemble genomes to high accuracy and require less hands-on filtering. 
To facilitate further exploration of our full set of global structural variation by the wider scientific community we 
have developed a visualisation and analysis tool. This resource will assist much-needed genomic investigations 
into P. falciparum, potentially leading to biological insights for the development of disease control measures.
Methods
sequence data. Illumina raw sequence data from more than 3,500 isolates in the Pf3k project were down-
loaded from the European Nucleotide Archive (see the project website, https://www.malariagen.net/projects/
pf3k). The raw sequences were aligned to the P. falciparum 3D7 genome using bwa-mem software (settings: –c 
100 –T 50)23, resulting in a mean coverage of 70.7-fold (Genic: 91.1-fold, Intergenic: 41.8-fold). SNPs and small 
indels (<15 bp) were called using SAMtools/BCFtools24 (default settings, version 1.6.1) and GATK software25 
(settings: “-T UnifiedGenotyper -ploidy 1 -glm BOTH -allowPotentiallyMisencodedQuals 2”, version 3.4–46). 
Isolates bearing abnormal coverage less than 20-fold or greater than 300-fold coverage were excluded to reduce 
false positive rates. Similarly, isolate samples with complex infections were excluded by accessing multiplicity 
of infection (MOI) as rates of missing and heterozygous SNP calls (>20%) and using estMOI software4 (>20% 
genome with MOI > 1; established using the standard point of inflection approach5). Specific SVs were further 
filtered by their phasing, as predicted by DELLY, as a secondary control against cryptic mixed infections (see 
below for the stringent heterozygous genotype filtering). After quality control, our dataset included 2,855 iso-
lates representing West Africa (n = 691), Central Africa (n = 344), East Africa (n = 464), South Asia (n = 43), 
Southeast Asia (n = 1,291), and South America (n = 22). The Pf3k Illumina data was supplemented by PacBio 
sequences (ERP009847) from 13 laboratory strains12,26,27, including 7G8 (Brazil), IT (Brazil), HB3 (Honduras), 
GA01 (Gabon), GN01 (Guinea), GB4 (Ghana), SN01 (Senegal), CD01 (Congo), KE01 (Kenya), SD01 (Sudan), 
DD2 (Indochina), KH01 (Cambodia), and KH02 (Cambodia).
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structural variant discovery. Structural variants were predicted from short read alignments against the 
latest 3D7 reference assembly using DELLY (v0.7.3), which has been found to be robust across a range of organ-
isms13. Smaller SVs, between 15 and 300 bp, were also identified with DELLY using the -i argument that utilises 
only soft-clipped read support. DELLY calling is considered more reliable for variants greater than 300 bp in 
length13, and our discussion of results is therefore predominantly of this group but recognises the presence of 
shorter variants of high frequency having strong support. The DELLY genotyping model (which assumes dip-
loidy) was employed to call heterozygous SVs. Variants longer than 100,000 base pairs were excluded as a con-
servative filter for erroneous calls. Variants identified within 100 kbp of a chromosome end and in var, rifin and 
stevor genes were removed due to established difficulties in accurately mapping these regions28.
Population-based SV Filtering and analysis. The SV-Pop (version 1.0) pipeline was utilised for 
post-discovery, population-based filtering of SVs and is publicly available from https://github.com/mattraven-
hall/SV-Pop. Population-wide filters were applied to exclude those variants with mean DELLY quality scores 
below 0.9, missingness >10%, an absence of paired read support, or homozygous reference calls frequency >10%. 
Variants were also removed if they displayed a heterozygous genotype frequency greater than 30%, as these sug-
gest cryptic mixed infections not identified at the SNP calling stage. This filter was not applied for the candidate 
gene analysis. Regional hotspots were identified using sums of isolates with variants in 1 kbp sliding windows with 
a 500 bp step size. Ultimately our approach produced three lists of candidate SVs: (i) over 1 million putative vari-
ants identified by DELLY alone (raw dataset), (ii) our primary “high quality” set of 70,858 SVs following filtering 
by SV-Pop (high-quality dataset), and (iii) 92,313 “high quality relaxed” candidate SVs following relaxation of the 
SV-Pop parameters to include heterozygous duplications (high-quality relaxed dataset).
Validation. The whole genomes from the 13 laboratory strains were used to validate any putative deletions 
and duplications detected by applying our discovery pipeline to the 2,855 isolates. Manual verification was per-
formed for all SVs found in regions specifically mentioned in this manuscript (e.g. in drug resistance genes), and 
involved examination of per-base coverage plots and read pair alignments with the 2,855 Illumina samples. To 
further confirm high quality SVs, deletions and duplications were also identified using CNVNator (v0.3.2; bin 
size of 400 bp)29 and by Control-FREEC (v11.0; window size 100 bp, window step 50 bp, ploidy of 1)11,30 software. 
Concordance statistics between the variants detected on the DELLY pipeline and these alternative approaches 
were derived on a per variant basis in 1 kbp windows. Using either CNVNator and/or Control-FREEC we con-
firmed 97.4% for all high-quality variants detected using our DELLY pipeline, and there was 95.3% concordance 
for the subset of variants greater than 100 bp.
Visualisation of variants. All SVs can be viewed using an online tool (http://genomics.lshtm.ac.uk/
PfGlobalSV/) (developed using SV-pop platform software31), where the full list of isolates (n = 2,855) with ENA 
codes are presented. This tool and our analysis compare variant frequencies between populations. Specifically, 
multi-population FST statistics were calculated between continent (Africa, Asia, South America) and region-based 
sub-populations (West Africa, Central Africa, East Africa, South Asia, Southeast Asia, South America) for both 
windows and variants using Nei’s method32.
Calculation of crt haplotype abundance. To determine the variability of crt in duplication positive iso-
lates, we conducted strict match read counts with high quality pre-alignment reads for five specific haplotypes. 
Haplotype sequences were 25 base pairs long, and included CVMVK (TGTATGTGTAATGAATAAAATTTTT), 
CVIET (TGTATGTGTAATTGAAACAATTTTT), CVIDT (TGTATGTGTAATTGATACAATTTTT), CVMET 
(TGTATGTGTAATGGAAACAATTTTT), and CVMNT (TGTATGTGTAATGAATACAATTTTT). Only 
CVIET and CVMNK haplotypes were observed in West Africa, and the proportion of CVIET reads for each 
isolate was calculated. These analyses were performed on the high-quality relaxed dataset.
Data Availability
For the primary short read data set, public accession numbers for the raw sequence data analysed are contained in 
SRA studies ERP000190 and ERP000199, as well as being accessible from the Pf3k project website (https://www.
malariagen.net/projects/pf3k). Raw PacBio sequence data is available from the European Nucleotide Archive 
(ERP009847).
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